CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 119 enrolled
Drug / intervention
DSXS +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02618759
NCT02618759Phase 3Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis

Sun Pharmaceutical Industries, Inc.·interventional·Posted Dec 1, 2015·Updated Dec 10, 2018

In Brief

A Phase 3 clinical trial evaluating DSXS and Placebo for Plaque Psoriasis. Completed, enrolled 119 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the therapeutic efficacy and safety of DSXS compared to a Placebo (vehicle) in patients with mild to moderate plaque psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 1, 2015
Enrollment StartAug 28, 2015
Primary CompletionMar 16, 2017
Study CompletionAug 25, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.6 years ago

Interventions

DSXSdrug

active treatment

Placebodrug

placebo treatment